Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Howard Liang Biography and Net Worth

CFO of BeiGene

Currently, Howard Liang holds the position of Chief Financial & Strategy Officer at BeiGene Ltd. Dr. Liang is also on the board of BeiGene (Guangzhou) Co., Ltd. and BeiGene Pharmaceuticals (Guangzhou) Co., Ltd. In the past Dr. Liang held the position of Senior Scientist at Abbott Laboratories, Principal at JMP Securities LLC, Vice President at A.G. Edwards & Sons, Inc., Managing Director at SVB Leerink LLC and Senior Analyst at Prudential Securities. Dr. Liang received an MBA and a doctorate from The University of Chicago and an undergraduate degree from Peking University.

What is Howard Liang's net worth?: The estimated net worth of Howard Liang is at least $301.71 million as of June 28th, 2021. Dr. Liang owns 1,553,149 shares of BeiGene stock worth more than $301,714,725 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Liang may own. Learn More about Howard Liang's net worth.
How do I contact Howard Liang?: The corporate mailing address for Dr. Liang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Howard Liang's contact information.
Has Howard Liang been buying or selling shares of BeiGene?: Howard Liang has not been actively trading shares of BeiGene over the course of the past ninety days. Most recently, Howard Liang sold 446 shares of the business's stock in a transaction on Monday, June 28th. The shares were sold at an average price of $365.00, for a transaction totalling $162,790.00. Following the completion of the sale, the chief financial officer now directly owns 1,553,149 shares of the company's stock, valued at $566,899,385. Learn More on Howard Liang's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 16 times. They sold a total of 95,368 shares worth more than $16,313,435.19. The most recent insider tranaction occured on October, 8th when CEO John Oyler sold 6,175 shares worth more than $1,433,958.50. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 10/8/2024.

Howard Liang Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/28/2021	Sell	446	$365.00	$162,790.00	1,553,149
6/7/2021	Sell	650	$354.16	$230,204.00	1,565,265
1/15/2021	Sell	12,600	$344.90	$4,345,740.00	1,573,715
12/14/2020	Sell	91,900	$229.04	$21,048,776.00	1,573,715
10/5/2020	Sell	14,000	$299.60	$4,194,400.00	168,415
9/14/2020	Sell	14,000	$250.27	$3,503,780.00	168,415
6/29/2020	Sell	300	$191.23	$57,369.00	168,415
6/8/2020	Sell	453	$170.84	$77,390.52	116,428
11/18/2019	Sell	25,000	$194.34	$4,858,500.00	122,317
6/27/2019	Sell	5,876	$9.47	$55,645.72	122,317
5/21/2019	Sell	23,200	$130.21	$3,020,872.00	52,338
5/6/2019	Sell	1,800	$130.01	$234,018.00	52,338
3/19/2018	Sell	40,000	$160.27	$6,410,800.00	15,872
3/16/2018	Sell	10,872	$157.07	$1,707,665.04	15,872
2/8/2016	Buy	65,000	$1.85	$120,250.00	65,000

Howard Liang Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $195.49

$191.92

$196.66

50 Day Range

MA: $212.26

$187.69

$246.04

2 Week Range

Now: $195.49

$126.97

$248.16

Volume

15,258 shs

Average Volume

264,840 shs

Market Capitalization

$19.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad